Heterogeneity of Cholangiocarcinoma Immune Biology.
cancer stem cells
cancer-associated fibroblasts
cholangiocarcinoma
heterogeneity
immune cells
liver
tumor microenvironment
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
received:
02
02
2023
revised:
04
03
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Cholangiocarcinomas (CCAs) are aggressive tumors arising along the biliary tract epithelium, whose incidence and mortality are increasing. CCAs are highly desmoplastic cancers characterized by a dense tumor microenvironment (TME), in which each single component plays a fundamental role in shaping CCA initiation, progression and resistance to therapies. The crosstalk between cancer cells and TME can affect the recruitment, infiltration and differentiation of immune cells. According to the stage of the disease and to intra- and inter-patient heterogeneity, TME may contribute to either protumoral or antitumoral activities. Therefore, a better understanding of the effect of each immune cell subtype may open the path to new personalized immune therapeutic strategies for the management of CCA. In this review, we describe the role of immune cells in CCA initiation and progression, and their crosstalk with both cancer-associated fibroblasts (CAFs) and the cancer-stem-cell-like (CSC) niche.
Identifiants
pubmed: 36980187
pii: cells12060846
doi: 10.3390/cells12060846
pmc: PMC10047186
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
CB receives honoraria from Astrazeneca (consultant, speaker, spouse employee), Incyte (consultant, speaker), Servier (consultant), Boehringer–Ingelheim (consultant); she receives research funds from Avacta, Medannex and Servier. JMB declares research grants (from Incyte and Albireo), personal fees for lecturer (from Astrazeneca), and consulting role (for QED Therapeutics, Albireo, OWL Metabolomics, Ikan Biotech CIMABay) The other authors declare no conflicts of interest.
Références
Hepatology. 2020 Sep;72(3):982-996
pubmed: 31879968
Asian Pac J Cancer Prev. 2012;13 Suppl:95-9
pubmed: 23480770
Neoplasia. 2019 Dec;21(12):1133-1142
pubmed: 31759251
Oncoimmunology. 2022 Feb 21;11(1):2035919
pubmed: 35223192
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Int J Cancer. 2004 Jan 10;108(2):173-80
pubmed: 14639599
Br J Cancer. 2018 Jan;118(2):171-180
pubmed: 29123259
Cancer Sci. 2016 Feb;107(2):116-22
pubmed: 26608587
Molecules. 2021 Oct 01;26(19):
pubmed: 34641520
Cancer Sci. 2020 Feb;111(2):323-333
pubmed: 31799781
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
FASEB J. 2013 Jan;27(1):13-24
pubmed: 23024375
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Oncotarget. 2018 Jul 06;9(52):29921-29933
pubmed: 30042823
Annu Rev Pathol. 2021 Jan 24;16:433-463
pubmed: 33264573
World J Gastroenterol. 2015 Apr 28;21(16):4961-8
pubmed: 25945010
World J Gastroenterol. 2020 Sep 7;26(33):4900-4918
pubmed: 32952338
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
Front Immunol. 2019 Aug 30;10:2035
pubmed: 31543877
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
J Clin Invest. 2020 Oct 1;130(10):5380-5396
pubmed: 32663198
Am J Pathol. 2022 Jun;192(6):826-836
pubmed: 35337836
Sci Rep. 2016 Oct 03;6:33789
pubmed: 27694951
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Eur J Pharmacol. 2020 Jun 15;877:173090
pubmed: 32234529
Ann Oncol. 2015 Sep;26(9):1910-1916
pubmed: 26037798
Liver Cancer. 2014 May;3(2):71-84
pubmed: 24944998
J Exp Clin Cancer Res. 2022 Apr 7;41(1):127
pubmed: 35392957
Mod Pathol. 2003 Oct;16(10):1019-27
pubmed: 14559985
Int J Oncol. 2005 Oct;27(4):973-80
pubmed: 16142313
Hepatology. 2013 Sep;58(3):1042-53
pubmed: 23505219
Dev Growth Differ. 2012 Jun;54(5):605-17
pubmed: 22680933
Hepatology. 1996 Jun;23(6):1341-4
pubmed: 8675149
Anticancer Res. 2017 Jun;37(6):3229-3237
pubmed: 28551669
J Hepatol. 2021 May;74(5):1145-1154
pubmed: 33276030
Hepatology. 2012 Jan;55(1):86-97
pubmed: 21898484
Hum Pathol. 2004 Jul;35(7):881-6
pubmed: 15257553
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Ann Surg Oncol. 2014 Apr;21(4):1314-22
pubmed: 24370904
Liver Int. 2019 May;39 Suppl 1:63-78
pubmed: 30907492
Int J Mol Sci. 2017 Jan 13;18(1):
pubmed: 28098760
J Hepatol. 2020 Nov;73(5):1118-1130
pubmed: 32505533
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33692217
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Nat Rev Immunol. 2007 Jul;7(7):543-55
pubmed: 17589544
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Nat Rev Gastroenterol Hepatol. 2011 Nov 29;9(1):44-54
pubmed: 22143274
Front Immunol. 2021 Mar 24;12:647209
pubmed: 33841428
Ann Surg Oncol. 2012 Aug;19(8):2506-14
pubmed: 22411204
Tumour Biol. 2015 Jul;36(7):5283-9
pubmed: 25672606
Front Oncol. 2019 Nov 15;9:1146
pubmed: 31799175
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Gut. 2022 Jul;71(7):1386-1398
pubmed: 34413131
J Allergy Clin Immunol. 2013 Sep;132(3):515-525
pubmed: 23993353
JHEP Rep. 2019 Jul 10;1(4):297-311
pubmed: 32039381
Chin Clin Oncol. 2016 Oct;5(5):62
pubmed: 27829276
Hepatology. 2013 Mar;57(3):1035-45
pubmed: 23172661
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
Hepatology. 2008 Feb;47(2):729-36
pubmed: 18167066
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443699
Biochem Biophys Res Commun. 2011 Jun 17;409(4):803-7
pubmed: 21624348
Cell Rep. 2022 Sep 20;40(12):111384
pubmed: 36130508
Immunity. 2014 Apr 17;40(4):569-81
pubmed: 24745333
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Nat Rev Immunol. 2014 Jul;14(7):447-62
pubmed: 24948366
J Clin Invest. 2015 Mar 2;125(3):1269-85
pubmed: 25689248
Transl Oncol. 2019 Feb;12(2):217-225
pubmed: 30415063
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Science. 1990 Jun 15;248(4961):1349-56
pubmed: 2113314
Cancer Cell Int. 2020 Dec 4;20(1):582
pubmed: 33292317
Am J Pathol. 2015 Jun;185(6):1724-39
pubmed: 25892683
In Vivo. 2018 Jul-Aug;32(4):771-781
pubmed: 29936458
Dig Dis Sci. 2013 Jun;58(6):1627-35
pubmed: 23306848
Surgery. 2018 Sep;164(3):411-418
pubmed: 29903509
Semin Immunopathol. 2019 Jan;41(1):49-58
pubmed: 30187086
Ann Oncol. 2022 Sep;33(9):929-938
pubmed: 35680043
Cancer Immunol Immunother. 2018 Oct;67(10):1579-1588
pubmed: 30056600
Int J Mol Sci. 2017 Jul 21;18(7):
pubmed: 28754000
J Leukoc Biol. 2019 Aug;106(2):309-322
pubmed: 30776148
J Physiol Pharmacol. 2013 Feb;64(1):109-14
pubmed: 23568978
Visc Med. 2016 Dec;32(6):422-426
pubmed: 28229077
Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51
pubmed: 22981632
Eur J Cancer. 2017 Nov;86:158-165
pubmed: 28988016
Biomark Res. 2022 Aug 16;10(1):59
pubmed: 35971182
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
J Autoimmun. 2019 Jun;100:17-26
pubmed: 30862450
Mol Ther. 2022 Aug 3;30(8):2800-2816
pubmed: 35526096
Br J Cancer. 2022 Sep;127(4):757-765
pubmed: 35597869
World J Gastrointest Oncol. 2012 May 15;4(5):94-102
pubmed: 22645632
Cancer Cell. 2021 Jun 14;39(6):866-882.e11
pubmed: 33930309
J Hepatol. 2017 Jan;66(1):102-115
pubmed: 27593106
Br J Cancer. 2022 Feb;126(2):219-227
pubmed: 34616011
Carcinogenesis. 2014 Mar;35(3):597-605
pubmed: 24293410
Blood. 1989 Nov 15;74(7):2527-34
pubmed: 2478233
Cell Cycle. 2015;14(4):481-7
pubmed: 25607528
Ann Hepatol. 2013 Mar-Apr;12(2):173-82
pubmed: 23396727
Nat Immunol. 2012 Dec;13(12):1145-54
pubmed: 23160217
J Surg Res. 2014 Nov;192(1):117-23
pubmed: 24909871
Biology (Basel). 2022 Jul 23;11(8):
pubmed: 35892954
Expert Opin Ther Targets. 2021 Oct;25(10):835-845
pubmed: 34806500
J Leukoc Biol. 2007 Dec;82(6):1375-81
pubmed: 17709402
Int J Cancer. 2012 Nov 15;131(10):2234-41
pubmed: 22337081
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Mol Cancer. 2010 Jan 24;9:13
pubmed: 20096135
Hepatology. 2022 Jan;75(1):28-42
pubmed: 34387870
Cancer Sci. 2018 Jul;109(7):2266-2274
pubmed: 29723922
Oncol Rep. 2009 Apr;21(4):957-69
pubmed: 19287994
Carcinogenesis. 2012 May;33(5):949-55
pubmed: 22425643
Cells. 2020 May 26;9(6):
pubmed: 32466488
EClinicalMedicine. 2021 Sep 16;41:101134
pubmed: 34585125
Cell Biochem Biophys. 2014 Nov;70(2):1311-6
pubmed: 24906237
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Gastroenterol. 2010 Aug;45(8):896-902
pubmed: 20379837
Gut. 2017 Jan;66(1):157-167
pubmed: 26452628
Int J Mol Sci. 2018 Sep 22;19(10):
pubmed: 30249019
Hepatology. 2022 Oct;76(4):982-999
pubmed: 35106794
J Hepatol. 2012 Oct;57(4):813-20
pubmed: 22727731
Cancer Immunol Immunother. 2021 May;70(5):1451-1464
pubmed: 33180184
J Surg Oncol. 2016 Jul;114(1):91-8
pubmed: 27111031
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
Br J Cancer. 2008 Nov 4;99(9):1375-9
pubmed: 18797460
J Cell Biochem. 2007 Jul 1;101(4):805-15
pubmed: 17226777
Hepatology. 2013 Dec;58(6):2001-11
pubmed: 23787814
Exp Hematol. 2004 Aug;32(8):748-55
pubmed: 15308326
Clin Exp Allergy. 2006 Nov;36(11):1436-45
pubmed: 17083354
J Cell Biochem. 2020 Apr;121(4):2828-2838
pubmed: 31692069
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
J Hepatol. 2022 Nov;77(5):1359-1372
pubmed: 35738508
Anticancer Res. 2012 Jun;32(6):2249-56
pubmed: 22641659
Int J Mol Sci. 2019 Aug 25;20(17):
pubmed: 31450710
Eur J Clin Invest. 2019 May;49(5):e13087
pubmed: 30767196
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Eur J Immunol. 2016 Feb;46(2):360-71
pubmed: 26541894
Oncol Lett. 2018 Jun;15(6):8681-8686
pubmed: 29805605
Eur J Cancer. 2019 Aug;117:84-90
pubmed: 31276980
Hepatology. 2021 Dec;74(6):3194-3212
pubmed: 34297412
Cytometry B Clin Cytom. 2019 Nov;96(6):490-495
pubmed: 30828998
Cell Immunol. 2021 Mar;361:104295
pubmed: 33508529
PLoS Negl Trop Dis. 2017 May 24;11(5):e0005614
pubmed: 28542159
Curr Opin Gastroenterol. 2020 Mar;36(2):70-76
pubmed: 31895228
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12250-12255
pubmed: 27791012
J Exp Med. 2012 Sep 24;209(10):1869-82
pubmed: 22927549
Cancer Lett. 2016 Sep 1;379(2):173-83
pubmed: 26123664
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Gastroenterology. 2014 Dec;147(6):1393-404
pubmed: 25181692
Hepatology. 2022 May;75(5):1154-1168
pubmed: 34719787
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Hepatology. 2008 Jan;47(1):90-6
pubmed: 18023027
Science. 2007 Aug 3;317(5838):666-70
pubmed: 17673663
Nat Commun. 2018 May 18;9(1):1988
pubmed: 29777108
Cancers (Basel). 2021 Mar 25;13(7):
pubmed: 33805904
Oncotarget. 2016 Nov 22;7(47):76604-76612
pubmed: 27780932
Br J Cancer. 2013 Nov 12;109(10):2665-74
pubmed: 24136146
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Gastroenterology. 2019 Oct;157(4):1067-1080.e9
pubmed: 31229495
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1435-1443
pubmed: 28757170
Gastroenterology. 2012 Apr;142(4):1021-1031.e15
pubmed: 22178589
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
HPB (Oxford). 2008;10(2):77-82
pubmed: 18773060
Cancer Immunol Immunother. 2016 Feb;65(2):141-50
pubmed: 26728479
EBioMedicine. 2021 May;67:103375
pubmed: 33993051
Trends Cancer. 2018 Mar;4(3):239-255
pubmed: 29506673
J Gastrointest Surg. 2007 Apr;11(4):445-51
pubmed: 17436128
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
J Hematol Oncol. 2022 Mar 28;15(1):37
pubmed: 35346322
Ann Surg Oncol. 2014 Aug;21(8):2684-98
pubmed: 24682719
World J Hepatol. 2017 Mar 28;9(9):455-468
pubmed: 28396716
J Hepatol. 2019 Apr;70(4):700-709
pubmed: 30553841